Levulinic Acid

Levulinic Acid

SCHEMBL113572

CC(=O)CCC(=O)O.CC(=O)CCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 1.00
SLC15A2 Q16348 1/20 1.00
ALDH1A1 P00352 1/20 0.71
EGLN1 Q9GZT9 6/20 0.64
ALKBH5 Q6P6C2 1/20 0.64
SUCNR1 Q9BXA5 1/20 0.64
PHF8 Q9UPP1 7/20 0.60
KDM2A Q9Y2K7 7/20 0.60
KDM5C P41229 4/20 0.60
KDM4E B2RXH2 3/20 0.60
KDM6B O15054 3/20 0.60
FFAR3 O14843 2/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
MAPK1 P28482 1/20 0.47
SLC13A3 Q8WWT9 1/20 0.47
OR51E2 Q9H255 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levulinic Acid SCHEMBL30530258 1.00
Levulinic Acid SCHEMBL27931545 1.00 LMNA (1.00) LMNASLC15A2ALDH1A1EGLN1ALKBH5
Levulinic Acid SCHEMBL20868 1.00
Levulinic Acid SCHEMBL2577171 0.97
Levulinic Acid SCHEMBL21815654 0.97
Levulinic Acid SCHEMBL8063365 0.97 LMNA (0.93) LMNASLC15A2ALDH1A1EGLN1ALKBH5
Levulinic Acid SCHEMBL21815797 0.97
Levulinic Acid SCHEMBL21815633 0.97
Levulinic Acid SCHEMBL10791504 0.97
Levulinic Acid SCHEMBL8061193 0.97 LMNA (0.93) LMNASLC15A2ALDH1A1EGLN1ALKBH5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028539-A1 COMPOSITIONS FOR PRODUCTION OF OLEFINS, TERPENES, AROMATICS AND CYCLOALIPHATICS AND METHODS THEREFOR, AND PRODUCTS THEREFROM VISOLIS INC (US) 2026-01-29 US claimed
EP-3063164-B1 SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES OTSUKA PHARMA CO LTD (JP) 2018-12-05 EP claimed
US-20120094836-A1 Biocide Compositions (III) COGNIS IP MANAGEMENT GMBH (DE) 2012-04-19 US claimed
WO-2011026580-A2 BIOCIDE COMPOSITIONS (IV) COGNIS IP MANAGEMENT GMBH (DE) 2011-03-10 WO claimed
EP-2292092-A1 Biocide compositions comprising esters of ketocarboxylic acids Cognis IP Management GmbH (DE) 2011-03-09 EP claimed
EP-2269451-A1 Biocide compositions (III) Cognis IP Management GmbH (DE) 2011-01-05 EP claimed
US-20260092130-A1 PROCESS FOR SYNTHESIZING POLYMER COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND VISOLIS INC (US) 2026-04-02 US disclosed
US-20260092228-A1 COMPOSITIONS FOR FUEL BLENDING MADE BY A SUSTAINABLE PROCESS, AND SUSTAINABLE FUEL COMPOSITIONS THEREFROM VISOLIS INC (US) 2026-04-02 US disclosed
US-20260092023-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS VISOLIS INC (US) 2026-04-02 US disclosed
US-20260055330-A1 HIGH ENERGY DENSITY ROCKET FUEL COMPOSITIONS VISOLIS INC (US) 2026-02-26 US disclosed
WO-2026022791-A1 HIGH ENERGY DENSITY ROCKET FUEL COMPOSITIONS Visolis, Inc. (US) 2026-01-29 WO disclosed
US-20260028540-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND VISOLIS INC (US) 2026-01-29 US disclosed
US-20260028545-A1 SUSTAINABLE AVIATION FUEL COMPOSITIONS VISOLIS INC (US) 2026-01-29 US disclosed
US-20010051632-A1 Phenyl-substituted indolizines and tetrahydroindolizines ORTHO MCNEIL PHARMACEUTICAL, INC. 2001-12-13 US disclosed
US-20010044439-A1 Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists ORTHO MCNEIL PHARMACEUTICAL, INC. 2001-11-22 US disclosed
WO-2001074815-A2 PHENYL-SUBSTITUTED IMIDAZOPYRIDINES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO disclosed
WO-2001074814-A1 PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO disclosed
WO-2001074813-A2 METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO disclosed
WO-2001074773-A2 PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO disclosed
WO-2001074810-A2 METHOD FOR USING 2-ARYLOXYALKYLAMINOBENZOXAZOLES AND 2-ARYLOXYALKYLAMINOBENZOTHIAZOLES AS H3 ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092228-A1 COMPOSITIONS FOR FUEL BLENDING MADE BY A SUSTAINABLE PROCESS, AND SUSTAINABLE FUEL COMPOSITIONS THEREFROM CYP4F12, CYP4F11, CYP4F8 LMNA 2643/4885SLC15A2 2596/4885ALDH1A1 700/4885
US-20260028540-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND AHR, COASY, YAP1 LMNA 1431/4885SLC15A2 2187/4885ALDH1A1 741/4885
US-20260092023-A1 PROCESS SYNTHESIZING SUSTAINABLE AVIATION FUEL COMPOSITIONS CYP4A11, HMGCR, FADS1 LMNA 1499/4885SLC15A2 2255/4885ALDH1A1 569/4885
US-20010044439-A1 Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists HRH3, HRH4, HRH2 LMNA 3594/4885SLC15A2 3995/4885ALDH1A1 1270/4885
US-20260055330-A1 HIGH ENERGY DENSITY ROCKET FUEL COMPOSITIONS HMGCR, CYP46A1, GGPS1 LMNA 1842/4885SLC15A2 3145/4885ALDH1A1 1657/4885
US-20260092130-A1 PROCESS FOR SYNTHESIZING POLYMER COMPOSITIONS FROM STARTING MATERIALS COMPRISING A DOUBLE BOND SAMM50, MAX, HSF1 LMNA 2269/4885SLC15A2 3436/4885ALDH1A1 1681/4885
US-20260028539-A1 COMPOSITIONS FOR PRODUCTION OF OLEFINS, TERPENES, AROMATICS AND CYCLOALIPHATICS AND METHODS THEREFOR, AND PRODUCTS THEREFROM CYP4F11, FDFT1, CYP4A11 LMNA 3663/4885SLC15A2 1068/4885ALDH1A1 413/4885
US-20010051632-A1 Phenyl-substituted indolizines and tetrahydroindolizines TPH2, TPH1, IDO2 LMNA 2489/4885SLC15A2 1992/4885ALDH1A1 967/4885
US-20260028545-A1 SUSTAINABLE AVIATION FUEL COMPOSITIONS CYP4F12, CYP4F11, CYP4F8 LMNA 1546/4885SLC15A2 1906/4885ALDH1A1 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.